Jörg Thomas Bittenbring1, Frank Neumann1, Bettina Altmann1, Marina Achenbach1, Jörg Reichrath1, Marita Ziepert1, Jürgen Geisel1, Evi Regitz1, Gerhard Held1, Michael Pfreundschuh2. 1. Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany. 2. Jörg Thomas Bittenbring, Frank Neumann, Marina Achenbach, Jörg Reichrath, Jürgen Geisel, Evi Regitz, Gerhard Held, and Michael Pfreundschuh, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; and Bettina Altmann and Marita Ziepert, University Leipzig, Leipzig, Germany. michael.pfreundschuh@uks.eu.
Abstract
PURPOSE: To investigate the impact and mechanisms of vitamin D deficiency (VDD) on the outcome of elderly patients with diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS: Three hundred fifty-nine pretreatment25-hydroxyvitamin D3 (25[OH]D3) serum levels from the RICOVER-60 study (Six Versus Eight Cycles of Biweekly CHOP-14 With or Without Rituximab in Elderly Patients With Aggressive CD20+ B-Cell Lymphomas) and 63 from the RICOVER-noRTh study (an amendment to the RICOVER-60 study in which patients received six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone administered at an interval of 2 weeks plus two cycles of rituximab [R-CHOP-14], but without radiotherapy) were determined by chemoluminescent immunoassay. Rituximab-mediated cellular cytotoxicity (RMCC) was assessed by lactate dehydrogenase release assay of CD20+ Daudi cells. RESULTS: RICOVER-60 patients with VDD (≤ 8 ng/mL) and vitamin D levels more than 8 ng/mL treated with rituximab had 3-year event-free survival (EFS) of 59% and 79% and 3-year overall survival (OS) of 70% and 82%, respectively. These differences were significant in a multivariable analysis adjusting for International Prognostic Index risk factors with a hazard ratio (HR) of 2.1 (P = .008) for EFS and 1.9 (P = .040) for OS. EFS was not significantly different in patients with vitamin D levels ≤ 8 or more than 8 ng/mL (HR, 1.2; P = .388) treated without rituximab. This was confirmed in an independent validation set of 63 RICOVER-noRTh patients. RMCC increased significantly (P < .001) in seven of seven individuals with VDD after substitution and normalization of their vitamin D levels. CONCLUSION:VDD is a risk factor for elderly patients with DLBCL treated with R-CHOP. That VDD impairs RMCC and substitution improves RMCC strongly suggests that vitamin D substitution enhances rituximab efficacy, which must be confirmed in appropriately designed prospective trials addressing VDD and substitution not only in DLBCL, but also in malignancies treated with other antibodies, of which the major mechanism of action is antibody-dependent cellular cytotoxicity (eg, trastuzumab in breast cancer and cetuximab in colorectal cancer).
RCT Entities:
PURPOSE: To investigate the impact and mechanisms of vitamin D deficiency (VDD) on the outcome of elderly patients with diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS: Three hundred fifty-nine pretreatment 25-hydroxyvitamin D3 (25[OH]D3) serum levels from the RICOVER-60 study (Six Versus Eight Cycles of Biweekly CHOP-14 With or Without Rituximab in Elderly Patients With Aggressive CD20+ B-Cell Lymphomas) and 63 from the RICOVER-noRTh study (an amendment to the RICOVER-60 study in which patients received six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone administered at an interval of 2 weeks plus two cycles of rituximab [R-CHOP-14], but without radiotherapy) were determined by chemoluminescent immunoassay. Rituximab-mediated cellular cytotoxicity (RMCC) was assessed by lactate dehydrogenase release assay of CD20+ Daudi cells. RESULTS: RICOVER-60 patients with VDD (≤ 8 ng/mL) and vitamin D levels more than 8 ng/mL treated with rituximab had 3-year event-free survival (EFS) of 59% and 79% and 3-year overall survival (OS) of 70% and 82%, respectively. These differences were significant in a multivariable analysis adjusting for International Prognostic Index risk factors with a hazard ratio (HR) of 2.1 (P = .008) for EFS and 1.9 (P = .040) for OS. EFS was not significantly different in patients with vitamin D levels ≤ 8 or more than 8 ng/mL (HR, 1.2; P = .388) treated without rituximab. This was confirmed in an independent validation set of 63 RICOVER-noRTh patients. RMCC increased significantly (P < .001) in seven of seven individuals with VDD after substitution and normalization of their vitamin D levels. CONCLUSION: VDD is a risk factor for elderly patients with DLBCL treated with R-CHOP. That VDD impairs RMCC and substitution improves RMCC strongly suggests that vitamin D substitution enhances rituximab efficacy, which must be confirmed in appropriately designed prospective trials addressing VDD and substitution not only in DLBCL, but also in malignancies treated with other antibodies, of which the major mechanism of action is antibody-dependent cellular cytotoxicity (eg, trastuzumab in breast cancer and cetuximab in colorectal cancer).
Authors: H Bruns; M Böttcher; M Qorraj; M Fabri; S Jitschin; J Dindorf; L Busch; R Jitschin; A Mackensen; D Mougiakakos Journal: Leukemia Date: 2016-12-23 Impact factor: 11.528
Authors: Leonardo Campiotti; Elena Bolzacchini; Matteo Basilio Sutter; Andrea Maria Maresca; Anna Maria Grandi; Luigina Guasti Journal: Intern Emerg Med Date: 2018-09-25 Impact factor: 3.397
Authors: Jennifer L Kelly; Gilles Salles; Bryan Goldman; Richard I Fisher; Pauline Brice; Oliver Press; Olivier Casasnovas; David G Maloney; Pierre Soubeyran; Lisa Rimsza; Corinne Haioun; Luc Xerri; Michael LeBlanc; Hervé Tilly; Jonathan W Friedberg Journal: J Clin Oncol Date: 2015-03-30 Impact factor: 44.544
Authors: Paige M Kulling; Kristine C Olson; Thomas L Olson; David J Feith; Thomas P Loughran Journal: Eur J Haematol Date: 2016-11-21 Impact factor: 2.997
Authors: Vladislava T Djurasinović; Biljana S Mihaljević; Sandra B Šipetić Grujičić; Svetlana D Ignjatović; Goran Trajković; Milena R Todorović-Balint; Darko A Antić; Jelena S Bila; Boško M Andjelić; Jelena J Jeličić; Vojin M Vuković; Aleksandra M Nikolic; Stanislaw Klek Journal: Support Care Cancer Date: 2018-03-06 Impact factor: 3.603
Authors: Da Jung Kim; Taeyun Kim; Jee-Yeong Jeong; Jae-Cheol Jo; Won Sik Lee; Ho-Jin Shin; Ji Hyun Lee; Ho Sup Lee Journal: Int J Hematol Date: 2020-01-06 Impact factor: 2.490